Journals / Dicle Tıp Dergisi / 2016 / Cilt: 43 - Sayı: 1

Serum Growth Arrest Speci fic Protein 6 (Gas-6) Levels in Patients with Schizophrenia

Şizofreni Hastalarında Serum Büyüme Durdurucu Spesifik Protein 6 (Gas-6) Düzeyleri

Pages
93–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: To reach a definitive data and better in- terpretation about the relationship between GAS-6 and schizophrenia, future studies with larger groups of pa- tients with schizophrenia subdivided by drug naïve and treated with antipsychotics/other treatment modalities and controls are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We have investigated serum growth ar- rest-specific protein 6 (GAS-6) levels from patients with schizophrenia divided into acute phase remission phases as well as control group.
📊
Key Findings & Data:The patients who were diagnosed with schizophrenia after regular psychiatric examination according to DSM- IV criteria (n=22) as well as control subjects were includ- ed in the study.
💡
Conclusion & Impact:Conclusion: To reach a definitive data and better in- terpretation about the relationship between GAS-6 and schizophrenia, future studies with larger groups of pa- tients with schizophrenia subdivided by drug naïve and treated with antipsychotics/other treatment modalities and controls are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We have investigated serum growth ar- rest-specific protein 6 (GAS-6) levels from patients with schizophrenia divided into acute phase remission phases as well as control group. Methods: This study was conducted in Psychiatry De- partment of Istanbul University Cerrahpasa Medical Fac- ulty. The patients who were diagnosed with schizophrenia after regular psychiatric examination according to DSM- IV criteria (n=22) as well as control subjects were includ- ed in the study. Schizophrenia patients with acute phase and remission phase were evaluated by Positive and Negative Syndrome Scale (PANSS) and Clinical global Impression Scale (CGI-S). The serum GAS-6 levels of schizophrenia patients during acute phase and remission phase were compared with the serum GAS-6 levels of healthy controls. Serum GAS-6 levels were measured by commercial ELISA kits. Results: No difference was found in serum GAS-6 levels among the three groups; schizophrenia with acute phase, schizophrenia with remission phase, and controls. There were no correlations between serum GAS-6 levels and PANSS and CGI scores. Conclusion: To reach a definitive data and better in- terpretation about the relationship between GAS-6 and schizophrenia, future studies with larger groups of pa- tients with schizophrenia subdivided by drug naïve and treated with antipsychotics/other treatment modalities and controls are needed.

Özet

Amaç: Çalışmamızda atak ve remisyon durumunda olan şizofreni hastaları ile kontrol grubunun serum büyüme durdurucu spesifik protein 6 (GAS-6) düzeylerini ölçerek bu gruplar arasında bir farklılık olup olmadığını araştırdık. Yöntemler: Çalışmamıza İstanbul Üniversitesi Cerrah- paşa Tıp Fakültesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı servisinde yatan; yapılan psikiyatrik muayenesinde DSM-IV-TR tanı kriterlerine göre ş izofreni tanısı konmuş hastalar (N=22) dahil edilmiştir. Hastaların klinik değer- lendirilmeleri psikotik atak ile hastaneye yatırıldığında ve remisyon esnasında Pozitif ve Negatif Sendrom Ölçeği (PANSS) ve Klinik Global İ zlenim Ölçeği (CGI-S) uygu- lanarak yapıldı. Hastaların psikotik atak esnasındaki ve remisyon sırasındaki serum GAS-6 düzeyleri sağlıklı kontrol grubunun düzeyleri ile karşılaştırıldı. Serum GAS- 6 analizleri ticari ELİZA kitleri ile yapılmıştır. Bulgular: Akut psikotik dönem ve remisyon döneminde- ki şizofreni hastalarının ve kontrol grubundaki kişilerin GAS-6 değerleri analiz edildiğinde bu ü ç grup arasında anlamlı bir fark bulunamamıştır. Serum GAS-6 düzeyleri ile PANSS ve CGI-S değerleri arasında herhangi bir kore- lasyon bulunmadığı görülmüştür. Sonuç: GAS-6 ve şizofreni arasındaki ilişkinin daha net olarak ortaya konulabilmesi için antipsikotik ve diğer ilaç kullanımlarının göz önünde bulundurulduğu daha fazla kişinin dahil edildiği kapsamlı çalışmaların yapılmasına ihtiyaç duyulmaktadır

🔖

Cite This Article

GERİN, F., BAŞ, A., EREK, A. T., ERMAN, H., DÜRÜYEN, S. (2016). Serum Growth Arrest Speci fic Protein 6 (Gas-6) Levels in Patients with Schizophrenia. Dicle Tıp Dergisi, Cilt: 43 - Sayı: 1, 93–98. https://ajindex.com/articles/202380

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Eşsizoğlu A, Yıldırım EA. Ruhsal bozuklukların psikobiyo- lojisinde nitrik oksit. Dicle Med J 2009;1:67-74
  2. Kaya MC, Güneş M, Bulut M, et al. Parmağını ampüte eden bir psikoz olgusu. Dicle Med J 2013;40:109-112
  3. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiol- ogy and treatment. Lancet Psychiatry. 2015;2:258–270
  4. Müller N, Weidinger E, Leitner B, et al. The role of inflam- mation in schizophrenia. Front Neurosci 2015;9:1-9 5. Gareeva AE, Traks T, Koks S, et al. The role of neurotropins and neuroxins genes in the risk of paranoid schizophrenia in Russian and Tatars. Genetika 2015;51:799–811
  5. Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizo- phrenia: A 30-year population-based register study. Am J Psychiatry 2011;168:1303–1310
  6. Prieto AL, Weber JL, Tracy S, et al. GAS-6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res 1999;816:646– 661
  7. Hsiao FC, Lin YF, Hsieh PS, et al. Circulating growth arrest- specific 6 protein is associated with adiposity, systemic in- flammation, and insulin resistance among overweight and obese adolescents. J Clin Endocrinol Metab 2013;98:267– 274
  8. Wu KS, Hung YJ, Lee CH, et al. The involvement of GAS- 6 signaling in the development of obesity and associated inflammation. Int J Endocrinol 2015;2015:1–7
  9. Ji R, Meng L, Li Q, et al. TAM receptor deficiency af- fects adult hippocampal neurogenesis. Metab Brain Dis 2015;30:633–44
  10. Ji R, Meng L, Jiang X, et al. TAM receptors support neural stem cell survival, proliferation and neuronal differentia- tion. PLoS One. 2014;9:1-16
  11. Ji R, Tian S, Lu HJ, et al. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell acti- vation. J Immunol. 2013;191:6165–6177
  12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276
  13. Kostakoğlu E, Batur S, Tiryaki A, et al. Reliability and va- lidity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turkish J Psychol 1999;14:23– 34
  14. Guy W. ECDEU Assessment Manual for Psychopharma- cology (028 Clinical Global Impressions [CGI]) Rockville, MD: National Institutes of Health. 1976;218–22
  15. Giangola MD, Yang WL, Rajayer S, et al. Growth arrest- specific protein 6 (GAS-6) protects against r